- Home
- CUB vs ABEO Comparison
CUB vs ABEO Comparison
Compare CUB & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUB
- ABEO
- Stock Information
- Founded
- CUB 2024
- ABEO 1974
- Country
- CUB United States
- ABEO United States
- Employees
- CUB N/A
- ABEO N/A
- Industry
- CUB
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- CUB
- ABEO Health Care
- Exchange
- CUB NYSE
- ABEO Nasdaq
- Market Cap
- CUB 315.9M
- ABEO 260.1M
- IPO Year
- CUB 2024
- ABEO 1980
- Fundamental
- Price
- CUB $10.36
- ABEO $5.27
- Analyst Decision
- CUB
- ABEO Strong Buy
- Analyst Count
- CUB 0
- ABEO 5
- Target Price
- CUB N/A
- ABEO $18.00
- AVG Volume (30 Days)
- CUB 31.8K
- ABEO 3.0M
- Earning Date
- CUB 01-01-0001
- ABEO 05-19-2025
- Dividend Yield
- CUB N/A
- ABEO N/A
- EPS Growth
- CUB N/A
- ABEO N/A
- EPS
- CUB N/A
- ABEO N/A
- Revenue
- CUB N/A
- ABEO N/A
- Revenue This Year
- CUB N/A
- ABEO N/A
- Revenue Next Year
- CUB N/A
- ABEO $539.93
- P/E Ratio
- CUB $45.28
- ABEO N/A
- Revenue Growth
- CUB N/A
- ABEO N/A
- 52 Week Low
- CUB $9.96
- ABEO $3.93
- 52 Week High
- CUB $10.55
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- CUB N/A
- ABEO 47.62
- Support Level
- CUB N/A
- ABEO $5.12
- Resistance Level
- CUB N/A
- ABEO $7.08
- Average True Range (ATR)
- CUB 0.00
- ABEO 0.58
- MACD
- CUB 0.00
- ABEO -0.04
- Stochastic Oscillator
- CUB 0.00
- ABEO 16.33
About CUB LIONHEART HOLDINGS
Lionheart Holdings is a blank check company.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.